TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33435904
Drug: Rifampicin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (300 mg bd)
Study: 33435904
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (up to 2000 mg daily)
Study: 34086541
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors including depressed mood, availability of illegal drugs, sensation-seeking behavior, social learning, peer's drug use
Study: 33183504
Drug: Transcatheter bariatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter bariatric embolotherapy (TBE) targeting the left gastric artery using an occlusion balloon microcatheter to administer 300- to 500-μm embolic beads; patients also entered a lifestyle counseling program.
Study: 33235284
Drug: Behavioral pharmacology
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral pharmacology (alcohol administration)
Study: 33235284
Drug: Medications that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications that reduced stimulation, sedation, and craving during alcohol administration
Study: 36100520
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of platelet-rich plasma
Study: 33583066
Drug: Norepinephrine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (all doses)
Study: 34099186
Drug: THC (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (15 mg, oral)
Study: 33898959
Drug: Aldafermin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 0.3 mg
Study: 35325622
Drug: Aldafermin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 1.0 mg
Study: 35325622
Drug: Aldafermin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 3.0 mg
Study: 32898998
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Occupational Health Coaching (REOHC), 2-hour sessions weekly for 12 weeks
Study: 35142814
Drug: Symptom monitoring
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom monitoring intervention (daily symptom reports displayed during oncology rounds)
Study: 34413633
Drug: Oxycodone 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.25 mg/h (low-dose group)
Study: 34413633
Drug: Oxycodone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.5 mg/h (control group)
Study: 32141306
Drug: Galvanic current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanic current electrotherapy with conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs) for 7 weeks, 3 times/week (20 sessions total)
Study: 32141306
Drug: Galvanic current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanic current electrotherapy with conservative treatment
Study: 32141306
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs)
Study: 36326824
Drug: High-dose convalescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose convalescent plasma (CCP)
Study: 36326824
Drug: Higher cumulative
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cumulative amount of neutralizing antibodies (subgroup of CCP)
Study: 36319597
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction (Cal-R) (25% restriction daily)
Study: 32454921
Drug: Sonophoresis procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sonophoresis procedures (0.9 W/cm2, 80% duty factor, 10 minutes duration) applied to the masticatory muscles with 25% Voltaren gel.
Study: 35845740
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (Group B)
Study: 33791673
Drug: TransFORM Body
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransFORM Body Treatment with TriHex Technology (TFB)
Study: 33791673
Drug: Regenerating Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerating Skin Nectar with TriHex Technology (RSN) + TransFORM Body Treatment with TriHex Technology (TFB)
Study: 35717995
Drug: BBV152 (COVAXIN);
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBV152 (COVAXIN); two 0.5 mL intramuscular doses on days 0 and 28.
Study: 35379563
Drug: Platinum-based doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet chemotherapy (standard care)
Study: 32928754
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed for men aged 15 to 24 years
Study: 32928754
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed for men aged 25 to 34 years
Study: 32365732
Drug: capsules with
Normalized name: Calcium Liquid Capsules with Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules with starch-adsorbed VitD (1000 IU; 25 µg daily)
Study: 32365732
Drug: oil-based Valens
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: oil-based Valens VitD oral spray (1000 IU; 25 µg daily)
Study: 32365732
Drug: water-based Valens
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: water-based Valens VitD oral spray (1000 IU; 25 µg daily)
Study: 35035867
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Ultrasound-guided stellate ganglion block + Extracorporeal shock wave therapy)
Study: 35830132
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of ascorbic acid (two days after irrigation treatment)
Study: 35830132
Drug: Non-consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-consumption of biological fertilizers
Study: 33570647
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents and anticoagulant therapy
Study: 36436541
Drug: Video laryngoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video laryngoscopy with supplemental oxygen (1 L/Kg per min)
Study: 36436541
Drug: Direct laryngoscopy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct laryngoscopy with supplemental oxygen (1 L/Kg per min)
Study: 33706870
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure treatment (<120 mm Hg)
Study: 33000539
Drug: Fissure sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fissure sealant therapy
Study: 32960955
Drug: Vacuum bell
Normalized name: BELLADONNA
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum bell therapy and physiotherapy
Study: 32960955
Drug: Vacuum bell
Normalized name: BELLADONNA
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum bell treatment only
Study: 35499204
Drug: SM-88 Regimen
Normalized name: Sm-88 component racemetyrosine
DrugBank: Racemetyrosine (DB16306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-88 Regimen (460 or 920 mg daily with methoxsalen, phenytoin, and sirolimus)
Study: 35168531
Drug: Bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 2.5 mg followed by combination treatment with bisoprolol 5 mg and amlodipine 5 mg
Study: 35168531
Drug: Bisoprolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (2.5 mg - 5 mg - 10 mg)
Study: 35168531
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with bisoprolol and amlodipine
Study: 34280656
Drug: Higher age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher age and longer duration of ICU treatment and mechanical ventilation
Study: 34787258
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus verapamil (n=26)
Study: 32388647
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic (LA) injection into the suprascapular notch
Study: 32388647
Drug: LA and
Normalized name: rubella and mumps virus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA and corticosteroid (CS) injections into the suprascapular notch
Study: 32388647
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (LA injection into the trapezius muscle)
Study: 33024268
Drug: Doublets ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublets ± bev or other treatments
Study: 34981666
Drug: 5-mg amlodipine
Normalized name: amlodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg amlodipine besylate tablets (generic formulation) in fasting trial
Study: 34981666
Drug: 5-mg amlodipine
Normalized name: amlodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg amlodipine besylate tablets (original formulation) in postprandial trial
Study: 32618279
Drug: ZPIV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV vaccine (5 μg) via standard regimen (weeks 0 and 4)
Study: 32618279
Drug: ZPIV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV vaccine (5 μg) via accelerated regimen (weeks 0 and 2)
Study: 32618279
Drug: ZPIV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPIV vaccine (5 μg) via single-dose regimen (week 0)
Study: 35953563
Drug: treatment‐as‐usual (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment‐as‐usual (control)
Study: 33724305
Drug: Conventional 7+3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 7+3 chemotherapy
Study: 35035849
Drug: Combined etomidate-ketamine
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined etomidate-ketamine anesthesia (etomidate 0.3 mg/kg + ketamine 0.5 mg/kg at 5 μg/kg/min)
Study: 36474274
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine (PQ) alongside standard artemisinin‐based combination therapy (ACT)
Study: 36474274
Drug: Standard artemisinin‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard artemisinin‐based combination therapy (ACT) without primaquine
Study: 34274921
Drug: Trimetazidine prolong
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine prolong 80 mg once daily
Study: 36253032
Drug: YLB113 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: YLB113 (50 mg subcutaneously every 2 weeks)
Study: 32080797
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light (BL) therapy for 45 minutes for 4 weeks
Study: 32080797
Drug: Dim Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim Light (DL) therapy for 45 minutes for 4 weeks
Study: 33060490
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with low tidal volume (LTV; 6-8 mL/kg)
Study: 33060490
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (CTV; 10-12 mL/kg)
Study: 35435086
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of boiled walnut taken daily as snacks
Study: 33314496
Drug: Sleep-restriction therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-restriction therapy (SRT)
Study: 35105176
Drug: Antibiotic-Eluting Envelope
Normalized name: Zaire ebolavirus envelope glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-Eluting Envelope (AEE)
Study: 34655181
Drug: Landiolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (10 μg/kg/min)
Study: 33432829
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (19.2 g/day for 18 months)
Study: 33211212
Drug: Once-weekly teriparatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly teriparatide (56.5 µg)
Study: 33211212
Drug: Once-weekly alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly alendronate (35 mg)
Study: 35978374
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) prior to speech-language therapy
Study: 35978374
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) concurrent with speech-language therapy
Study: 35978374
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) following speech-language therapy
Study: 35978374
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation (speech-language therapy only)
Study: 34208742
Drug: Bis-Hexanoyl (R)-1,3-Butanediol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bis-Hexanoyl (R)-1,3-Butanediol (BH-BD) 12.5 g (Days 0–7) and 25 g (Days 7–28)
Study: 33683337
Drug: Tandem Fluzone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem Fluzone High-Dose vaccination (2 doses)
Study: 33683337
Drug: Standard-of-care vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care vaccination (single-dose)
Study: 32859638
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) with concurrent resistance mutation
Study: 32859638
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) without concurrent mutations
Study: 32859638
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) with non-pathogenic, non-resistance co-mutation
Study: 36266613
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% (w/w) applied twice daily for 6 weeks
Study: 36266613
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% (w/w)
Study: 36266613
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical gel
Study: 616673046
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IR‐A and MEL
Study: 36284454
Drug: Additional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional analgesic consumption
Study: 83020338
Drug: apomorphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: apomorphine (5 mg)
Study: 83020338
Drug: amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: amantadine (200 mg)
Study: 32299679
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy (randomized arm)
Study: 32299679
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy (open-label comparison)
Study: 32299679
Drug: Ramipril therapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril therapy (combined analysis)
Study: 35301512
Drug: Low-dose vedolizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vedolizumab (100 or 150 mg for patients <30 kg; 200 or 300 mg for patients ≥30 kg)
Study: 35301512
Drug: High-dose vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose vedolizumab (100 or 150 mg for patients <30 kg; 200 or 300 mg for patients ≥30 kg)
Study: 35301512
Drug: Both low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low and high-dose vedolizumab
Study: 34861036
Drug: Third BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third BNT162b2 mRNA vaccine dose
Study: 34477812
Drug: MCI Gel
Normalized name: samarium Sm153 50 MCI/ML [Quadramet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI Gel
Study: 35997659
Drug: Cluster 2
Normalized name: CLUSTER FIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster 2 (Almost Daily, High Pain)
Study: 34606123
Drug: Herbal remedies
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal remedies (polyherbal decoction every 8 hr and two herbal capsules every 12 hr) plus standard care for 7 days
Study: 32360596
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (200,000 IU initially, then 100,000 IU monthly)
Study: 33083489
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin gel with scaling and root planing (SRP) for 7 days
Study: 34034143
Drug: IN-MLV (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN-MLV (n = 11): 2 mL of IN MLV vaccine containing BHV1, BRSV, and BPI3V (Inforce3®)
Study: 34034143
Drug: SC-MLV (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-MLV (n = 10): 2 mL of MLV vaccine containing BHV1, BRSV, BPI3V, and BVDV1 & 2 (Bovi-Shield GOLD® 5)
Study: 32331021
Drug: Cariprazine 3-12
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3-12 mg/d (flexible dosing)
Study: 32815418
Drug: Ablation as
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation as an adjunct to cardiac surgery
Study: 33709997
Drug: SBIRT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT program with brief motivational intervention and referral to specialized treatment
Study: 33725776
Drug: In-hospital physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital physiotherapy (daily post-operative physiotherapy intervention including individualized mobilization, breathing exercises, ambulation with or without a walking aid)
Study: 34714938
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (PGE1; 25 μg)
Study: 34714938
Drug: Slow-release dinoprostone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release dinoprostone (PGE2; 10 μg)
Study: 34469399
Drug: No experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No experimental treatment program (control group)
Study: 34162019
Drug: Unani formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unani formulations
Study: 33809996
Drug: L-Glutamine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine supplementation (Gln) with physical exercises (PE + Gln)
Study: 33809996
Drug: L-Glutamine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine supplementation (Gln) without physical exercises (NPE + Gln)
Study: 33809996
Drug: L-Glutamine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine supplementation (Gln)
Study: 32134713
Drug: Resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (250 mg tablet)
Study: 32134713
Drug: Estradiol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (0.05 mg/day transdermal patch)
Study: 35709465
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy
Study: 35709465
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy alone (standard therapy)
Study: 35709465
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and cisplatin induction chemotherapy
Study: 33046233
Drug: Left ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left ventricular reshaping with a beating heart implant
Study: 32094049
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no implant)
Study: 35786597
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) first-line therapy in combination with chemotherapy
Study: 35786597
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) third-line or later monotherapy
Study: 32068914
Drug: Licogliflozin 10
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 10 mg
Study: 32068914
Drug: Licogliflozin 50
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 50 mg
Study: 35622105
Drug: Intermittent Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Sequential Pneumatic Compression (ISPC) device
Study: 34318635
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository (0.1 g/suppository)
Study: 35279835
Drug: PCSK9-inhibiting monoclonal
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-inhibiting monoclonal antibodies
Study: 34749739
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily on top of standard of care for 28 days
Study: 35440808
Drug: Office blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office blood pressure before treatment
Study: 35440808
Drug: Office blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office blood pressure in the on-treatment follow-up period
Study: 35075723
Drug: Topical/nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical/nasal administration of a probiotic assemblage (PA) of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A